Officer operator, by operations. you XXXX year this conference Thank Medical's Helius welcome LaViscount, Vice our and to President Joyce and General our Chief call and fourth Manager joined Canadian and full quarter Financial of Mark Leno, call. and on today Operating our I'm Officer; earnings everyone Chief
provide on me of recent with as with we Let and intermediate continued what the progress agenda value. to brief begin long-term a our on have Helius to create today strategy reposition part regulatory update and to strategy going shareholder a we are remarks made. US of I'll you focus quick my our
and on expectations sheet enter an made some review Following have the our commercial as this additional progress our results, discussion, balance financial condition, thoughts update in XXXX. secure our quarter recent Canada. to our share Mark with you we will on capital, fourth provide activities and Joyce then will enhance we
thoughts update call and share questions. in With get let's remarks, some US near-term the outlook an longer-term that, regulatory on on Joyce's progress. initiatives Following started for before we our open strategy will our I and with XXXX closing
pursuing for PoNS an is indication our the March obtaining clearance or As MS as US for in of pathway our in regulatory sclerosis, device. XXXX, US we multiple focused strategy announced first the
patient unmet a high target represents -- large need. a Our indication medical population with need
States, As one estimated there are the MS. to a reminder, living be patients with in million United approximately
provide treatment has deficit MS and with is the pandemic, improve gait the potential significantly MS PoNS we made throughout that impact and strong life. patients which their may obtaining non-drug onset the indication May non-implantable quality COVID-XX to device Despite the to the a breakthrough progress aim submitting of request Our their FDA and safety of clearance greatly August designation our of FDA on X. classification device novo de XXXX, from to our for in for walking,
we information fourth which we de XXXX, for review novo quarter a XX request, FDA October days the XX. the request on approximately During of for our from the received process additional into announced
reminder, the additional agency goal clock de As were to XX% sponsor. FDA's that for for stops review a provide request from decision submitted receives of the until the is novo response XXXX. A a stated in FDA's a days the within the information XXX requests
to swiftly thorough the response request. FDA's submit prepare worked affairs Our and team regulatory a to
they response our conducted each to requested. request of address of information an part effort, of with precisely the As of this goal aligning aspect the the analysis
during we look review the our were announce response in forward half novo FDA's continued of FDA's US of to clearance XX our we XXXX. result a to that de hope We novo formal January submitted classification efforts, request As first of de and their proud the to and the receive on request.
Services the or development Coverage of Medicare for new addition we by will represents pathway of or the our closely devices, as devices. FDA strong medical receive MCIT provide In breakthrough Medicare breakthrough early for as & national developed pace front, as same Medicaid clearance Technology CMS. clearance rule. Medicare to the progress Innovative for MCIT day of Medicare FDA-designated have been on a to which Centers coverage coverage the MCIT regulatory the the monitoring
choose to Medicare be coverage for Importantly, potentially start coverage, able start device commercial their enabling of them the a to align with of date launch manufacturers will device. the
in coverage obtain the limited and and were fourth work fourth the four tailwind MCIT initial MCIT to quarter years coverage CMS Mark our information represents With XX clearance. activities Canada. January However, from potential provide finalizing Medicare, is to to move an approximately commercialization will review that revenue pathway CMS on completed XX. Leno on on with forward during on of public via the Americans to they more rule date their collection continue a million this important our to period an quarter activities. of comments enrolled and obtaining now forward commercial performance you in our with to update efforts US of the look with and we implementation announced
